Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma.
Simple Summary: Cancer immunotherapy using combinations of checkpoint inhibitor antibodies has shown high levels of clinical activity in the treatment of metastatic melanoma. These agents often produce complete remissions of wide-spread melanoma and long-term survival. All current cancer immunothera...
| Publicado en: | Cancers Vol. 18; no. 14; pp. 2349 - 2362 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |